• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.

作者信息

Kelly Catherine M, Pritchard Kathleen I

出版信息

J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.

DOI:10.1093/jnci/djs139
PMID:22395645
Abstract
摘要

相似文献

1
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.细胞色素P450 2D6基因分型作为绝经后女性辅助性他莫昔芬获益的标志物：经验教训
J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.
2
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31.
3
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.关于：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31.
4
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验 以及 回复：CYP2D6和UGT2B7基因分型与他莫昔芬治疗的乳腺癌患者复发风险
J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.
5
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.CYP2D6 和 UGT2B7 基因型与他莫昔芬治疗的乳腺癌患者复发风险。
J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.
6
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.CYP2D6 基因型与内分泌治疗反应性乳腺癌绝经后妇女的关系：乳腺国际研究组 1-98 试验。
J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.
7
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.关于：细胞色素P450 2D6的药物基因组变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1331-2; author reply 132-3. doi: 10.1093/jnci/djn272. Epub 2008 Sep 9.
8
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.关于：细胞色素P450 2D6的药物基因组学变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1331; author reply 1332-4. doi: 10.1093/jnci/djn269. Epub 2008 Sep 9.
9
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.导管原位癌的内分泌治疗：权衡风险与获益
Lancet. 2016 Feb 27;387(10021):819-21. doi: 10.1016/S0140-6736(15)01219-2. Epub 2015 Dec 11.
10
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.细胞色素P450 2D6（CYP2D6）基因分型不应用于决定绝经后乳腺癌患者的他莫昔芬治疗方案。
J Clin Oncol. 2013 Jul 20;31(21):2753-5. doi: 10.1200/JCO.2013.49.4278. Epub 2013 Jun 17.

引用本文的文献

1
Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models.影响他莫昔芬在乳腺癌患者中药代动力学的因素：群体药代动力学模型的系统评价
Biology (Basel). 2022 Dec 28;12(1):51. doi: 10.3390/biology12010051.
2
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.CYP2D6 药物遗传学和个体化医学中的表型转化。
Expert Opin Drug Metab Toxicol. 2022 Nov;18(11):769-785. doi: 10.1080/17425255.2022.2160317. Epub 2023 Jan 3.
3
Clinical Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.
临床基因分型以实现雌激素受体阳性乳腺癌患者辅助他莫昔芬治疗的个体化：争议现状
Cancers (Basel). 2021 Feb 12;13(4):771. doi: 10.3390/cancers13040771.
4
Breast cancer recurrence in relation to antidepressant use.乳腺癌复发与抗抑郁药使用的关系。
Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.
5
Germline oncopharmacogenetics, a promising field in cancer therapy.生殖系肿瘤药物遗传学，癌症治疗中一个有前景的领域。
Cell Oncol (Dordr). 2015 Feb;38(1):65-89. doi: 10.1007/s13402-014-0214-4. Epub 2015 Jan 9.
6
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.乳腺癌中CYP2D6基因座杂合性缺失：对种系药物遗传学研究的启示。
J Natl Cancer Inst. 2014 Dec 8;107(2):dju401. doi: 10.1093/jnci/dju401.
7
Status of adjuvant endocrine therapy for breast cancer.乳腺癌辅助内分泌治疗现状。
Breast Cancer Res. 2014;16(2):206. doi: 10.1186/bcr3636.
8
Addressing phenoconversion: the Achilles' heel of personalized medicine.应对表型转换：个性化医疗的致命弱点。
Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441.
9
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.与他莫昔芬疗效相关的代谢和转运：持续争议的新视角。
Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168.
10
CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.CYP2D6 基因型与他莫昔芬治疗乳腺癌反应：系统评价和荟萃分析。
PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013.